Cardiomyopathy Trial, Recruiting (NCT06866912)

Cardiomyopathy Trial, Recruiting NCT06866912 Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna Condition: Cardiomyopathy

Printed from Voxsanity (voxsanity.com.au) — NCT06866912 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Cardiomyopathy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with a condition called amyloidosis (a disease where abnormal proteins build up in the body's organs and tissues)
You carry a gene change (mutation) in the transthyretin gene but do not yet have symptoms
You are at least 18 years old at the time of your diagnosis
You are willing and able to give your consent to take part in the trial

Who may not be able to join:

There are no listed exclusion criteria for this trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Simone Longhi, MD, IRCCS Azienda Ospedaliero-Universitaria di Bologna

Phone: 00390512149039

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06866912

Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna

Phase: Not Applicable

Status: Recruiting

Condition: Cardiomyopathy

Trial contact: 00390512149039

More information: https://clinicaltrials.gov/study/NCT06866912

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with a condition called amyloidosis (a disease where abnormal proteins build up in the body's organs and tissues)
You carry a gene change (mutation) in the transthyretin gene but do not yet have symptoms
You are at least 18 years old at the time of your diagnosis
You are willing and able to give your consent to take part in the trial

Who may not be able to join:

There are no listed exclusion criteria for this trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Registry

ClinicalTrials.gov

Start date

1 September 2023

Est. completion

31 August 2033

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

prevalence of amyloidosis; incidence of amyloidosis; Observational epidemiological study of patients with systemic amyloidosis; Types of cardiac clinical phenotype; Incidence of mixed clinical phenotype; Incidence of hospitalization for heart failure; Incidence of hospitalization for onset of arrhythmias; Incidence of hospitalization for stroke; incidence of pacemaker implantation; incidence of pacemaker implantation of defibrillator; Incidence of cardiac transplantation; Incidence of transplantation of other solid organs; Mortality

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov